Can-Fite BioPharma (NYSE:CANF) Stock Price Up 0.3% – What’s Next?

Shares of Can-Fite BioPharma Ltd. (NYSE:CANF) shot up 0.3% during trading on Tuesday . The stock traded as high as $3.27 and last traded at $3.16. 20,962 shares traded hands during trading, a decline of 98% from the average daily volume of 1,143,556 shares. The stock had previously closed at $3.15.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CANF. D. Boral Capital upgraded shares of Can-Fite BioPharma from a “hold” rating to a “buy” rating in a research note on Wednesday, May 13th. Zacks Research upgraded shares of Can-Fite BioPharma to a “hold” rating in a research note on Wednesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (up from $5.00) on shares of Can-Fite BioPharma in a research note on Thursday, July 2nd. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $44.00.

Can-Fite BioPharma Stock Performance

The firm has a 50 day moving average of $3.24 and a two-hundred day moving average of $3.58. The stock has a market cap of $2.07 million, a P/E ratio of -1.77 and a beta of 1.11.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new stake in Can-Fite BioPharma stock. Jane Street Group LLC purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 205,004 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned 15.66% of Can-Fite BioPharma at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).